Twist Bioscience

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Twist Bioscience 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About TWST

Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. It operates through the following geographical segments: Americas, EMEA, and APAC. 

CEO
Emily Marine Leproust
CEOEmily Marine Leproust
Employees
979
Employees979
Headquarters
San Francisco, California
HeadquartersSan Francisco, California
Founded
2013
Founded2013
Employees
979
Employees979

TWST Key Statistics

Market cap
2.01B
Market cap2.01B
Price-Earnings ratio
-23.81
Price-Earnings ratio-23.81
Dividend yield
Dividend yield
Average volume
1.50M
Average volume1.50M
High today
$33.21
High today$33.21
Low today
$30.42
Low today$30.42
Open price
$31.15
Open price$31.15
Volume
1.17M
Volume1.17M
52 Week high
$55.33
52 Week high$55.33
52 Week low
$23.30
52 Week low$23.30

Stock Snapshot

With a market cap of 2.01B, Twist Bioscience(TWST) trades at $32.81. The stock has a price-to-earnings ratio of -23.81.

As of 2025-12-04, Twist Bioscience(TWST) stock has fluctuated between $30.42 and $33.21. The current price stands at $32.81, placing the stock +7.9% above today's low and -1.2% off the high.

Twist Bioscience(TWST) shares are trading with a volume of 1.17M, against a daily average of 1.5M.

In the last year, Twist Bioscience(TWST) shares hit a 52-week high of $55.33 and a 52-week low of $23.30.

In the last year, Twist Bioscience(TWST) shares hit a 52-week high of $55.33 and a 52-week low of $23.30.

TWST News

Simply Wall St 5h
Is Twist’s New Endotoxin‑Controlled Plasmid DNA Offering Altering The Investment Case For TWST?

Twist Bioscience recently launched research-grade Plasmid DNA Preps to support pharmaceutical and biotech customers’ preclinical studies, offering animal origin...

Is Twist’s New Endotoxin‑Controlled Plasmid DNA Offering Altering The Investment Case For TWST?

Analyst ratings

90%

of 10 ratings
Buy
90%
Hold
10%
Sell
0%

People also own

Based on the portfolios of people who own TWST. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.